Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling
Crossref DOI link: https://doi.org/10.1038/s41401-021-00708-2
Published Online: 2021-06-29
Published Print: 2022-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yao, Jing-yue
Xu, Shu
Sun, Yue-ning
Xu, Ye
Guo, Qing-long
Wei, Li-bin
Text and Data Mining valid from 2021-06-29
Version of Record valid from 2021-06-29
Article History
Received: 2 March 2021
Accepted: 28 May 2021
First Online: 29 June 2021
Competing interests
: The authors declare no competing interests.